Nuveen
URGN icon

Nuveen’s UroGen Pharma URGN Stock Holding History

Nuveen’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39M Buy
92,102
+4,580
+5% +$124K ﹤0.01% 2312
2026
Q1 		$1.57M Sell
87,522
-215,079
-71% -$4.31M ﹤0.01% 2364
2025
Q4 		$7.09M Sell
302,601
-204,930
-40% -$4.45M ﹤0.01% 1753
2025
Q3 		$10.1M Buy
507,531
+424,385
+510% +$7.62M ﹤0.01% 1548
2025
Q2 		$1.14M Sell
83,146
-9,811
-11% -$94.1K ﹤0.01% 2545
2025
Q1 		$1.03M Hold
92,957
– – ﹤0.01% 2635
2024
Q4 		$990K Sell
92,957
-56,430
-38% -$676K ﹤0.01% 2716
2024
Q3 		$1.9M Buy
149,387
+56,430
+61% +$838K ﹤0.01% 2437
2024
Q2 		$1.56M Buy
92,957
+9,538
+11% +$136K ﹤0.01% 2504
2024
Q1 		$1.25M Hold
83,419
– – ﹤0.01% 2606
2023
Q4 		$1.25M Buy
83,419
+19,785
+31% +$257K ﹤0.01% 2624
2023
Q3 		$892K Buy
63,634
+2,172
+4% +$34.9K ﹤0.01% 2620
2023
Q2 		$636K Buy
+61,462
New +$678K ﹤0.01% 2852
2022
Q2 		– Sell
-94,660
Closed -$854K – 3487
2022
Q1 		$854K Buy
94,660
+908
+1% +$7.08K ﹤0.01% 2867
2021
Q4 		$906K Sell
93,752
-6,564
-7% -$92.5K ﹤0.01% 2890
2021
Q3 		$1.67M Buy
100,316
+3,716
+4% +$58.9K ﹤0.01% 2756
2021
Q2 		$1.48M Sell
96,600
-6,054
-6% -$109K ﹤0.01% 2843
2021
Q1 		$2M Sell
102,654
-95,036
-48% -$2.02M ﹤0.01% 2622
2020
Q4 		$3.56M Sell
197,690
-42,558
-18% -$892K ﹤0.01% 2240
2020
Q3 		$4.63M Sell
240,248
-96,901
-29% -$2.19M ﹤0.01% 1957
2020
Q2 		$8.81M Buy
337,149
+66,316
+24% +$1.62M ﹤0.01% 1565
2020
Q1 		$4.83M Buy
+270,833
New +$7.32M ﹤0.01% 1733
2019
Q4 		– Sell
-45,444
Closed -$1.08M – 3270
2019
Q3 		$1.08M Buy
45,444
+2,618
+6% +$85.6K ﹤0.01% 2666
2019
Q2 		$1.54M Buy
+42,826
New +$1.58M ﹤0.01% 2555

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Nuveen's URGN Position: Q2 2026 in Review

Nuveen increased its UroGen Pharma (URGN) stake by 5.2% in Q2 2026, buying an estimated $124K and bringing the position to 92,102 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2312.

Nuveen first reported a position in URGN in Q2 2019 and has held it in 24 quarters since. The position peaked at $10.1M in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Nuveen held 92,102 shares of UroGen Pharma worth $3.39M as of Q2 2026.
  • Nuveen bought 4,580 UroGen Pharma shares in Q2 2026, an estimated $124K.
  • UroGen Pharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2312 holding.
  • Nuveen first reported a position in UroGen Pharma in Q2 2019 and has held it in 24 quarters since.
  • Nuveen's UroGen Pharma position peaked at $10.1M in Q3 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.